Objectives: To compare the efficacy, safety, immunogenicity and pharmacokinetics (PK) of SB2 to the infliximab reference product (INF) in patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate therapy.
HOPE study demonstrates that local inflammation is a suitable target for treatment in patients with debilitating disease1
In clinical practice, broad global assessments of psoriasis disease activity and its effect on patients' quality of life are used to assess the severity of patients' disease and their response to treatment.
Study emphasises the need for weight loss interventions alongside symptomatic treatment in patients with psoriatic arthritis1
Recent improvements in RA management may be driving positive change
Cyclosporine, azathioprine and mycophenolate mofetil proved to be effective in consolidating and maintaining remission after 10 years follow up1
Introducing biomarker into clinical practice could enable more effective prevention of cardiovascular disease
Approximately two thirds of patients experience treatment success following glucocorticoid tapering1
As glucocorticoids and immunosuppressive drugs are non-specific therapeutic agents that cause many adverse reactions, the development of biologicals aiming to control specific molecular targets is anticipated for the treatment of systemic lupus erythematosus (SLE).